Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation Research
Search: search_blue_button Advanced Search
Circulation Research. 2008;102:1359-1367
Published online before print May 8, 2008, doi: 10.1161/CIRCRESAHA.108.174235
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
102/11/1359    most recent
CIRCRESAHA.108.174235v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Caprio, M.
Right arrow Articles by Jaffe, I. Z.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Caprio, M.
Right arrow Articles by Jaffe, I. Z.
Related Collections
Right arrow ACE/Angiotension receptors
Right arrow Gene regulation
Right arrow Endothelium/vascular type/nitric oxide
Right arrow Mechanism of atherosclerosis/growth factors
(Circulation Research. 2008;102:1359.)
© 2008 American Heart Association, Inc.


Molecular Medicine

Functional Mineralocorticoid Receptors in Human Vascular Endothelial Cells Regulate Intercellular Adhesion Molecule-1 Expression and Promote Leukocyte Adhesion

Massimiliano Caprio, Brenna G. Newfell, Andrea la Sala, Wendy Baur, Andrea Fabbri, Giuseppe Rosano, Michael E. Mendelsohn, Iris Z. Jaffe

From the Molecular Cardiology Research Institute (B.G.N., W.B., M.E.M., I.Z.J.), Department of Medicine-Division of Cardiology, Tufts Medical Center and Tufts University School of Medicine, Boston, Mass; Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele Pisana (M.C., A.l.S., G.R.), Rome, Italy; and Unit of Endocrinology (M.C., A.F.), Ospedale Sant’Eugenio, University Tor Vergata, Rome, Italy.

Correspondence to Iris Z. Jaffe, MD, PhD, Tufts Medical Center, Molecular Cardiology Research Institute, 800 Washington St, Box 80, Boston, MA 02111. E-mail ijaffe{at}tuftsmedicalcenter.org

In clinical trials, aldosterone antagonists decrease cardiovascular mortality and ischemia by unknown mechanisms. The steroid hormone aldosterone acts by binding to the mineralocorticoid receptor (MR), a ligand-activated transcription factor. In humans, aldosterone causes MR-dependent endothelial cell (EC) dysfunction and in animal models, aldosterone increases vascular macrophage infiltration and atherosclerosis. MR antagonists inhibit these effects without changing blood pressure, suggesting a direct role for vascular MR in EC function and atherosclerosis. Whether human vascular ECs express functional MR is not known. Here, we show that human coronary artery and aortic ECs express MR mRNA and protein and that EC MR mediates aldosterone-dependent gene transcription. Human ECs also express the enzyme 11-β-hydroxysteroid dehydrogenase-2 (11βHSD2), and inhibition of 11βHSD2 in aortic ECs enhances gene transactivation by cortisol, supporting that EC 11βHSD2 is functional. Furthermore, aldosterone stimulates transcription of the proatherogenic leukocyte–EC adhesion molecule intercellular adhesion molecule (ICAM)1 gene and protein expression on human coronary artery ECs, an effect inhibited by the MR antagonist spironolactone and by MR knock down with small interfering RNA. Cell adhesion assays demonstrate that aldosterone promotes leukocyte–EC adhesion, an effect that is inhibited by spironolactone and ICAM1 blocking antibody, supporting that aldosterone induction of EC ICAM1 surface expression via MR mediates leukocyte–EC adhesion. These data show that aldosterone activates endogenous EC MR and proatherogenic gene expression in clinically important human ECs. These studies describe a novel mechanism by which aldosterone may influence ischemic cardiovascular events and support a new explanation for the decrease in ischemic events in patients treated with aldosterone antagonists.


Key Words: mineralocorticoid receptor • endothelial cell • aldosterone • spironolactone • ICAM1




This article has been cited by other articles:


Home page
HypertensionHome page
A. M. Dorrance
Are Macrophages the Foot Soldiers in the War Waged by Aldosterone Against the Heart?
Hypertension, September 1, 2009; 54(3): 451 - 453.
[Full Text] [PDF]


Home page
J Mol EndocrinolHome page
A. J Rickard and M. J Young
Corticosteroid receptors, macrophages and cardiovascular disease
J. Mol. Endocrinol., June 1, 2009; 42(6): 449 - 459.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
F. Waanders, H. Rienstra, M. W. Boer, A. Zandvoort, J. Rozing, G. Navis, H. van Goor, and J.-L. Hillebrands
Spironolactone ameliorates transplant vasculopathy in renal chronic transplant dysfunction in rats
Am J Physiol Renal Physiol, May 1, 2009; 296(5): F1072 - F1079.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
Y. Jeong, D. F. Chaupin, K. Matsushita, M. Yamakuchi, S. J. Cameron, C. N. Morrell, and C. J. Lowenstein
Aldosterone activates endothelial exocytosis
PNAS, March 10, 2009; 106(10): 3782 - 3787.
[Abstract] [Full Text] [PDF]